Innate Pharma Files 6-K Report
Ticker: IPHYF · Form: 6-K · Filed: Sep 30, 2024 · CIK: 1598599
| Field | Detail |
|---|---|
| Company | Innate Pharma SA (IPHYF) |
| Form Type | 6-K |
| Filed Date | Sep 30, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, press-release
TL;DR
Innate Pharma filed a 6-K on 9/30/24, likely with a press release attached. Check for updates.
AI Summary
Innate Pharma SA filed a Form 6-K on September 30, 2024, reporting a press release dated the same day. The filing does not contain specific financial figures or operational updates beyond the reporting of the press release itself.
Why It Matters
This filing indicates Innate Pharma is providing an update to the SEC, likely related to a press release, which could contain material information for investors.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that primarily serves to attach a press release, without disclosing new financial data or significant operational changes within the filing itself.
Key Players & Entities
- Innate Pharma SA (company) — Registrant
- September 30, 2024 (date) — Date of report and press release
- 001-39084 (other) — Commission File Number
FAQ
What is the primary purpose of this 6-K filing?
The primary purpose of this 6-K filing is to report a press release dated September 30, 2024, as required for foreign private issuers.
What is the Commission File Number for Innate Pharma SA?
The Commission File Number for Innate Pharma SA is 001-39084.
What is the address of Innate Pharma SA's principal executive office?
The address of Innate Pharma SA's principal executive office is 117 Avenue de Luminy—BP 30191, 13009 Marseille, France.
Does Innate Pharma SA file annual reports under Form 20-F or 40-F?
Innate Pharma SA indicates it files annual reports under Form 20-F.
What exhibit is included with this 6-K filing?
Exhibit 1.1 included with this 6-K filing is a Press Release dated September 30, 2024.
Filing Stats: 164 words · 1 min read · ~1 pages · Grade level 9.5 · Accepted 2024-09-30 06:15:13
Filing Documents
- a6k-iphx240930.htm (6-K) — 9KB
- exhibit991-240930.htm (EX-99.1) — 18KB
- 0001598599-24-000075.txt ( ) — 28KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. INNATE PHARMA S.A. Date September 30, 2024 By s HERVE BRAILLY Name Herv Brailly Title Chairman of the Executive Board and Chief Executive Officer